<html><head><title>Peter Emch emch</title>
<meta http-equiv="Content-Type" content="text/html">
<meta http-equiv="Author" name="Peter Emch" content="emch">
<meta http-equiv="Author" name="emch" content="company">
<meta name="Language" content="de-en">
<meta name="Keywords" lang="de" content="emch, Peter Emch, company">
<meta name="Keywords" lang="en" content="Peter Emch, emch, , company">
<meta name="Description" lang="al "content=" Another analyst downgraded the company from "strong buy" to "neutral. " Apparently many investors, however, and some analysts, saw Renal Care's warning as a sign of clarity rather than concern. In a written opinion issued after a conference call with Renal Care executives yesterday, Credit Suisse First Boston analyst Peter Emch said the earnings warning had been expected by investors. He said that served to drive down the company's stock. "The guidance of slower growth has been widely anticipated by investors, and in our opinion, resulted in few investors willing to purchase shares in front of such an announcement," Emch said.">
<meta name="Revisit-after" content="1 month">
<meta name="Date_modified" content="2001-06-13">
<meta name="ROBOTS" content="index,follow">
</head>
<style type="text/css"> 
	A.nav:link {TEXT-DECORATION: none}
	A.nav:visited {TEXT-DECORATION: none} 
	A.nav:visited {TEXT-DECORATION: none}
	A.nav:active {TEXT-DECORATION: none}
	A.nav:hover {TEXT-DECORATION: none}
	</style><body bgcolor="#FFFFF">
	<font face="arial" size="3" color="#000000">
	<table border="0" cellpadding="0" cellspacing="0" width="100%">
	<tr><td><a href="company.html" class="nav">company</a></td></tr>
	<tr><td><a href="index.html" class="nav">home page</a></td></tr></table>
	<br><div align="center"><font size="6">- emch -<br><br></font></div>
<table width="100%" border="0" cellspacing="0" cellpadding="1">
<td valign="bottom">
 Quotes are delayed 15 minutes for Nasdaq, 20 minutes otherwise (except on designated real-time quote page). . CSFB analyst Peter Emch raises his estimates on DaVita Inc. Information contained on this page is provided to CNET directly from the investment firm cited in this report. The information herein was obtained from sources which Bloomberg L.</td>
<tr>
</table>
<table width="100%" border="0" cellspacing="2" cellpadding="5">
<td valign="bottom"><img HEIGHT="331" WIDTH="102" src="http://www.tennessean.com/sii/99/02/02//graphics/globalside.gif"></td>
<td valign="top">
 Almost half of the 5,000 hospitals in the United States are in small-town markets, a large potential market that CHS is expected to exploit. "The margins are good and it's an easy story to tell," said Frank Morgan, who follows health-care companies for J. and others that go after bigger hospitals, said Peter Emch, an analyst with Credit Suisse First Boston in Baltimore. CHS, which owns or operates 47 hospitals with 4,115 beds -- primarily in nonurban markets -- overnight could become the largest public hospital company of its kind based on number of hospitals. Its closest competitor, Health Management Associates of Naples, Fla.</td>
<tr>
</table>
<table width="100%" border="0" cellspacing="0" cellpadding="5"
<td valign="bottom">
 . outlined a sweeping overhaul Thursday that would end some of the practices that led to a federal criminal probe, curb acquisitions and slow the company's rapid growth. But it's also likely to cut into the lucrative chain's 13 to 15 percent annual profit growth, said Peter Emch, an analyst at Alex. Department spokeswoman Carole Florman declined to comment on the plan, but said the department encourages providers to implement "meaningful corporate integrity programs. The company has hired law and accounting firms to conduct an independent investigation but wanted to make changes first, said Jack Bovender, who became Columbia's president on Monday.</td>
<td valign="top"><img HEIGHT="268" WIDTH="182" src="http://www.irisharchitect.com/iarchct/no134/html/../images/134_2506.jpg"></td>
<tr>
</table>
<table width="100%" border="0" cellspacing="2" cellpadding="6">
<td valign="center"><img height="160" width="120" src="http://a1144.g.akamai.net/7/1144/1175/v032/img.bizjournals.com/market/albany/bookoflists.gif"></td>
<td valign="bottom">
 Another analyst downgraded the company from "strong buy" to "neutral. " Apparently many investors, however, and some analysts, saw Renal Care's warning as a sign of clarity rather than concern. In a written opinion issued after a conference call with Renal Care executives yesterday, Credit Suisse First Boston analyst Peter Emch said the earnings warning had been expected by investors. He said that served to drive down the company's stock. "The guidance of slower growth has been widely anticipated by investors, and in our opinion, resulted in few investors willing to purchase shares in front of such an announcement," Emch said.</td>
<tr>
</table>
<br>also look at: <a href="http://www.tennessean.com/gallery">http://www.tennessean.com/gallery</a><br><br>
</font><font size=-6> <a class="nav" href="clone/376/index.html">.</a><br><br>
</font></body></html>
